The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Cited by
Sorted by citations
Items 801–900 of 1,007
Nabbouh, A. I., Hleihel, R., Saliba, J. L., Karam, M., Hamie, M., Wu, H.-C., Berthier, C., Tawil, N., Bonnet, P., Deleuze‐Masquéfa, C., et al. (2017) · Cancer · doi:10.1002/cncr.30515 · Cited by 38
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia
Laing, A. A., Harrison, C. J., Gibson, B. E. S., & Keeshan, K. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.007 · Cited by 38
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39
Tarlock, K., Zhong, S., He, Y., Ries, R. E., Severson, E. A., Bailey, M., Morley, S., Balasubramanian, S., Erlich, R., Lipson, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25443 · Cited by 41
Castelli, G., Pelosi, E., & Testa, U. (2019) · Cancers · doi:10.3390/cancers11020260 · Cited by 39
Su, L., Gao, S., Tan, Y., Lin, H., Liu, X., Liu, S., Yang, Y., Sun, J., & Li, W. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03699-7 · Cited by 38
Carbonell, D., Suárez‐González, J., Chicano, M., Andrés-Zayas, C., Triviño, J. C., Rodríguez‐Macías, G., Bastos‐Oreiro, M., Font, P., Ballesteros, M., Muñiz, P., et al. (2019) · Cancers · doi:10.3390/cancers11091364 · Cited by 38
Werstein, B., Dunlap, J. B., Cascio, M. J., Ohgami, R. S., Fan, G., Press, R. D., & Raess, P. W. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.11.004 · Cited by 38
Vial, J., Lechevalier, N., Lacombe, F., Dumas, P., Bidet, A., Leguay, T., Vergez, F., Pigneux, A., & Béné, M. C. (2021) · Cancers · doi:10.3390/cancers13040629 · Cited by 38
Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias
Swatler, J., Turos-Korgul, L., Kozłowska, E., & Piwocka, K. (2021) · Cancers · doi:10.3390/cancers13061203 · Cited by 38
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia
Awad, S. A., Kankainen, M., & Mustjoki, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894652 · Cited by 39
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Egbuna, C., Patrick-Iwuanyanwu, K. C., Onyeike, E. N., Khan, J., & Alshehri, B. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1969286 · Cited by 38
Comprehensive evaluation of computational methods for predicting cancer driver genes
Shi, X., Teng, H., Shi, L., Bi, W., Wei, W., Mao, F., & Sun, Z. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab548 · Cited by 39
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 43
Somatic SETBP1 mutations in myeloid neoplasms
Makishima, H. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2241-1 · Cited by 38
Wang, Q., Cai, W., Wang, Q., Zhu, M., Yan, L., Yu, Y. P., Bao, X., Shen, H., Yao, H., Xie, J., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26758 · Cited by 37
Tokaz, M. C., Baldomero, H., Cowan, A. J., Saber, W., Greinix, H. T., Koh, M., Kröger, N. M., Mohty, M., Galeano, S., Okamoto, S., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.12.013 · Cited by 37
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
Wei, A. H., & Roberts, A. W. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000912 · Cited by 37
Joint inference of exclusivity patterns and recurrent trajectories from tumor mutation trees
Luo, X. G., Kuipers, J., & Beerenwinkel, N. (2023) · Nature Communications · doi:10.1038/s41467-023-39400-w · Cited by 41
Xie, J., Sheng, M., Rong, S., Zhou, D., Wang, C., Wu, W., Huang, J., Sun, Y., Wang, Y., Chen, P., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02055-z · Cited by 39
Loscocco, G. G., Rotunno, G., Mannelli, F., Coltro, G., Gesullo, F., Pancani, F., Signori, L., Maccari, C., Esposito, M., Paoli, C., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27136 · Cited by 37
Immunotherapeutic targeting of surfaceome heterogeneity in AML
Bordeleau, M.-È., Audemard, E. O., Métois, A., Thérêt, L., Lisi, V., Farah, A., Spinella, J.-F., Chagraoui, J., Moujaber, O., Aubert, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114260 · Cited by 37
Hernández‐Sánchez, A., González, T., Sobas, M., Sträng, E., Castellani, G., Abáigar, M., Valk, P. J. M., Ramiro, Á. V., Benner, A., Metzeler, K. H., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02333-4 · Cited by 37
Self-citationQin, Y., Pu, X., Hu, D., & Yang, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-68755-3 · Cited by 37
Qu, Y., Siggens, L., Cordeddu, L., Gaidzik, V. I., Karlsson, K., Bullinger, L., Döhner, K., Ekwall, K., Lehmann, S., & Lennartsson, A. (2016) · Blood · doi:10.1182/blood-2016-07-726877 · Cited by 40
Self-citationGreil, R., Hutterer, E., Hartmann, T. N., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0155-9 · Cited by 37
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 38
RTK-RAS pathway mutation is enriched in myeloid sarcoma
Choi, M., Jeon, Y. K., Sun, C.-H., Yun, H., Hong, J., Shin, D., Kim, I., Yoon, S., & Koh, Y. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0083-6 · Cited by 37
Wen, L., Xu, Y., Li, Y., Wang, N., Wang, Q., Liu, T., Pan, J., Cen, J., Zhou, H., Miao, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.205369 · Cited by 37
Molecular landscape and targeted therapy of acute myeloid leukemia
Gu, R., Yang, X. W., & Wei, H. (2018) · Biomarker Research · doi:10.1186/s40364-018-0146-7 · Cited by 37
Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications
Hartmann, L., & Metzeler, K. H. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22756 · Cited by 42
Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia
Giri, B., Gupta, V. K., Yaffe, B., Modi, S., Roy, P., Sethi, V., Lavania, S., Vickers, S. M., Dudeja, V., Banerjee, S., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1901-8 · Cited by 37
Yang, L., Wang, L., Yang, Z., Jin, H., Zou, Q., Zhan, Q., Tang, Y., Tao, Y., Li, L., Jing, Y., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30223 · Cited by 37
Chaturvedi, A., Gupta, C., Gabdoulline, R. R., Borchert, N. M., Goparaju, R., Kaulfuß, S., Görlich, K., Schottmann, R., Othman, B., Welzenbach, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.236992 · Cited by 39
Self-citationBewersdorf, J. P., Shallis, R. M., Gowda, L., Wei, W., Hager, K. M., Isufi, I., Kim, T. K., Pillai, M. M., Seropian, S., Podoltsev, N. A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1759051 · Cited by 37
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
Chen, K., Yang, Q., Zha, J., Deng, M., Zhou, Y., Fu, G., Bi, S., Feng, L.-Y., Xu-Monette, Z. Y., Chen, X. L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02972-2 · Cited by 37
Tremblay, C. S., Chiu, S. K., Saw, J., McCalmont, H., Litalien, V., Boyle, J. A., Sonderegger, S., Chau, N., Evans, K., Cerruti, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20091-6 · Cited by 37
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Peretz, C. A. C., McGary, L. H. F., Kumar, T., Jackson, H., Jacob, J. P., Durruthy-Durruthy, R., Levis, M. J., Perl, A. E., Huang, B. J., & Smith, C. C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003398 · Cited by 37
Kaeding, A., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., Correnti, C., Loken, M. R., Brodersen, L. E., Pardo, L. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004424 · Cited by 37
Nishida, Y., Zhao, R., Heese, L. E., Akiyama, H., Patel, S., Jaeger, A. M., Jacamo, R. O., Kojima, K., Ma, M. C. J., Ruvolo, V. R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01308-z · Cited by 37
Konuma, T., Kanda, J., Kuwatsuka, Y., Yanada, M., Kondo, T., Hirabayashi, S., Kako, S., Akahoshi, Y., Uchida, N., Doki, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4856 · Cited by 37
Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
Vonk, C. M., Hinai, A. S. A. A., Hanekamp, D., & Valk, P. J. M. (2021) · Cancers · doi:10.3390/cancers13215431 · Cited by 37
Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1
Oreskovic, E., Wheeler, E. C., Mengwasser, K. E., Fujimura, E., Martin, T. D., Tóthová, Z., & Elledge, S. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120540119 · Cited by 37
Konuma, T., Mizuno, S., Kondo, T., Arai, Y., Uchida, N., Takahashi, S., Tanaka, M., Kuriyama, T., Miyakoshi, S., Onizuka, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00678-6 · Cited by 37
Emdal, K. B., Palacio‐Escat, N., Wigerup, C., Eguchi, A., Nilsson, H., Bekker‐Jensen, D. B., Rönnstrand, L., Kazi, J. U., Puissant, A., Itzykson, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111177 · Cited by 37
Eckardt, J., Stasik, S., Röllig, C., Sauer, T., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., Steffen, B., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00790-1 · Cited by 37
Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease
Martignoles, J., Delhommeau, F., & Hirsch, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123850 · Cited by 46
Pathogenic Mechanisms in Acute Myeloid Leukemia
Chakraborty, S., & Park, C. Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01021-8 · Cited by 36
Didi, I., Alliot, J., Dumas, P., Vergez, F., Tavitian, S., Largeaud, L., Bidet, A., Rieu, J., Luquet, I., Lechevalier, N., et al. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107437 · Cited by 36
Shimony, S. O., Bewersdorf, J. P., Shallis, R. M., Liu, Y., Schaefer, E. J., Zeidan, A. M., Goldberg, A. D., Stein, E. M., Marcucci, G., Lindsley, R. C., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02175-0 · Cited by 36
Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress
Do, B. T., Hsu, P. P., Vermeulen, S. Y., Wang, Z., Hirz, T., Abbott, K. L., Aziz, N., Replogle, J. M., Bjelosevic, S., Paolino, J. D., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.05.010 · Cited by 36
Silva, H. J., Martin, G. A., Birocchi, F., Wehrli, M., Kann, M. C., Supper, V. M., Parker, A., Graham, C., Bratt, A., Bouffard, A. A., et al. (2024) · Blood · doi:10.1182/blood.2023023210 · Cited by 37
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Europe PMC (PubMed Central) · Cited by 36
Novel therapeutic options in Acute Myeloid Leukemia
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.09.001 · Cited by 36
Aldoss, I. T., Pham, A. T., Li, S. M., Gendzekhadze, K., Afkhami, M., Telatar, M., Hong, H., Padeganeh, A., Bedell, V., Cao, T. M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.172544 · Cited by 37
INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia
Jin, H., Yang, L., Wang, L., Yang, Z., Zhan, Q., Tao, Y., Zou, Q., Tang, Y., Xian, J., Zhang, S., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0675-9 · Cited by 36
Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia
Daneshbod, Y., Kohan, L., Taghadosi, V., Weinberg, O. K., & Arber, D. A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0612-y · Cited by 36
Bewersdorf, J. P., Ardasheva, A., Podoltsev, N. A., Singh, A., Biancon, G., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100587 · Cited by 37
Xu, L., Durruthy-Durruthy, R., Eastburn, D. J., Pellegrino, M., Shah, O., Meyer, E. H., & Zehnder, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47297-z · Cited by 36
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 38
Zambetti, N. A., Firestone, A. J., Remsberg, J. R., Huang, B. J., Wong, J. C. Y., Long, A. M., Predovic, M., Suciu, R. M., Sheth, A. I., Kogan, S. C., et al. (2020) · Blood · doi:10.1182/blood.2019003530 · Cited by 36
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Fenwarth, L., Fournier, É., Cheok, M. H.-C., Boyer, T., Gonzales, F., Castaigné, S., Boissel, N., Lambert, J., Dombret, H., Preudhomme, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165626 · Cited by 36
Advancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia
Haferlach, T. (2020) · Hematology Reports · doi:10.4081/hr.2020.8957 · Cited by 36
Yurchenko, A. A., Padioleau, I., Matkarimov, B. T., Soulier, J., Sarasin, A. R., & Nikolaev, S. I. (2020) · Nature Communications · doi:10.1038/s41467-020-19633-9 · Cited by 38
Non‐genetic heterogeneity, altered cell fate and differentiation therapy
Lewis, A. C., & Kats, L. M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012670 · Cited by 36
Autophagy a Close Relative of AML Biology
Joffre, C., Ducau, C., Poillet-Perez, L., Courdy, C., & Mas, V. M. (2021) · Biology · doi:10.3390/biology10060552 · Cited by 36
Simonetti, G., Mengucci, C., Padella, A., Fonzi, E., Picone, G., Delpino, C., Nanni, J., Tommaso, R. D., Franchini, E., Papayannidis, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01318-x · Cited by 40
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Stasik, S., Eckardt, J., Krämer, M., Röllig, C., Krämer, A., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004631 · Cited by 36
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
Oñate, G., Bataller, Á., Garrido, A., Hoyos, M., Arnán, M., Vives, S., Coll, R., Tormo, M., Sampol, A., Escoda, L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004136 · Cited by 37
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Roloff, G. W., & Griffiths, E. A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020206 · Cited by 36
Liu, L., Vujovic, A., Deshpande, N., Sathe, S., Anande, G., Chen, H. T., Xu, J., Minden, M. D., Yeo, G. W.-M., Unnikrishnan, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31155-0 · Cited by 37
Kotini, A. G., Carcamo, S., Cruz‐Rodriguez, N., Olszewska, M., Wang, T., Demircioğlu, D., Chang, C.-J., Bernard, E., Chao, M. P., Majeti, R., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0167 · Cited by 37
Song, C., Wang, L., Wu, X., Wang, K., Xie, D., Xiao, Q., Li, S., Jiang, K., Liao, L., Yates, J. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3091 · Cited by 37
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Estey, E. H., & Gale, R. P. (2017) · Leukemia · doi:10.1038/leu.2017.56 · Cited by 36
Differentiation Syndrome in Acute Leukemia: APL and Beyond
Woods, A. C., & Norsworthy, K. J. (2023) · Cancers · doi:10.3390/cancers15194767 · Cited by 35
Nishida, Y., Ishizawa, J., Ayoub, E., Montoya, R. H., Ostermann, L. B., Müftüoğlu, M., Ruvolo, V. R., Patsilevas, T., Scruggs, D. A., Khazaei, S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh1436 · Cited by 37
Chan, O., Ali, N. H. A., Tashkandi, H., Ellis, A., Ball, S., Grenet, J. E., Hana, C. K., Deutsch, Y. E., Zhang, L., Hussaini, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011173 · Cited by 35
Culver‐Cochran, A. E., Hassan, A., Hueneman, K. M., Choi, K., Ma, A. I., VanCauwenbergh, B., O'Brien, E. J., Wunderlich, M., Perentesis, J. P., & Starczynowski, D. T. (2024) · Nature Communications · doi:10.1038/s41467-024-53629-z · Cited by 37
Therapy-related myeloid neoplasms
Ganser, A., & Heuser, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000316 · Cited by 35
Self-citationMesenchymal stromal cells in myeloid malignancies
Schroeder, T. A., Geyh, S., Germing, U., & Haas, R. R. (2016) · Blood Research · doi:10.5045/br.2016.51.4.225 · Cited by 38
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia
Jacquel, A., Mazed, F., Saland, E., Larrue, C., Mondésir, J., Birsen, R., Green, A. S., Lambert, M., Sujobert, P., Gautier, E., et al. (2017) · Leukemia · doi:10.1038/leu.2017.284 · Cited by 35
Terada, K., Yamaguchi, H., Ueki, T., Usuki, K., Kobayashi, Y., Tajika, K., Gomi, S., Kurosawa, S., Saito, R., Furuta, Y., et al. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22542 · Cited by 36
Tien, F., Hou, H., Tang, J., Kuo, Y., Chen, C., Tsai, C., Yao, M., Lin, C., Li, C., Huang, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.189043 · Cited by 35
Patel, N. M., Jo, H., Eberhard, D. A., Yin, X., Hayward, M. C., Stein, M. K., Hayes, D. N., & Grilley‐Olson, J. E. (2018) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000684 · Cited by 35
Borišek, J., Saltalamacchia, A., Spinello, A., & Magistrato, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00635 · Cited by 43
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Fiorentini, A., Capelli, D., Saraceni, F., Menotti, D., Poloni, A., & Olivieri, A. (2020) · Oncology and Therapy · doi:10.1007/s40487-019-00108-x · Cited by 35
Jeong, P., Moon, Y., Lee, J., Lee, S., Park, J., Lee, J.-E., Kim, J., Lee, H., Kim, N. Y., Choi, J., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112205 · Cited by 35
Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
Wang, S., Wu, Z., Li, T., Li, Y., Wang, W., Hao, Q., Xie, X., Wan, D., Jiang, Z., Wang, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69194-6 · Cited by 35
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Jeon, J. Y., Buelow, D. R., Garrison, D. A., Niu, M., Eisenmann, E. D., Huang, K. M., Thomas, M. E. Z., Weber, R. H., Whatcott, C. J., Warner, S. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140169 · Cited by 35
Wang, E. S., & Baron, J. I. (2020) · Hematology · doi:10.1182/hematology.2020000089 · Cited by 35
The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AML
Guo, C., Gao, Y.-Y., Ju, Q., Zhang, C.-X., Gong, M., & Li, Z. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02914-2 · Cited by 36
Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia
Sariani, O. K., Eghbalpour, S., Kazemi, E., Buzhani, K. R., & Zaker, F. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155508 · Cited by 36
Kanagal‐Shamanna, R., Bravo, G. M., Sasaki, K., Jabbour, E., Bueso-Ramos, C., Wei, Y., Chien, K., Kadia, T., Ravandi, F., Borthakur, G., et al. (2021) · Cancer · doi:10.1002/cncr.33745 · Cited by 39
A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemia
Chen, Z., Song, J., Wang, W., Bai, J., Zhang, Y., Shi, J., Bai, J., & Zhou, Y. (2021) · American Journal of Hematology · doi:10.1002/ajh.26309 · Cited by 35
Fornerod, M. W. J., Ma, J., Noort, S., Liu, Y., Walsh, M. P., Shi, L., Nance, S., Liu, Y., Wang, Y., Song, G., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0049 · Cited by 35
Yun, H., Narayan, N., Vohra, S., Giotopoulos, G., Mupo, A., Madrigal, P., Sasca, D., Lara‐Astiaso, D., Horton, S. J., Singh, S. A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00925-9 · Cited by 38
Bill, M., Jentzsch, M., Bischof, L., Kohlschmidt, J., Grimm, J., Schmalbrock, L. K., Backhaus, D., Brauer, D., Goldmann, K., Franke, G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005789 · Cited by 35
CircZBTB46 Protects Acute Myeloid Leukemia Cells from Ferroptotic Cell Death by Upregulating SCD
Long, F., Lin, Z., Long, Q., Lu, Z., Zhu, K., Zhao, M., & Yang, M. (2023) · Cancers · doi:10.3390/cancers15020459 · Cited by 36
Tripodo, C., Burocchi, A., Piccaluga, P. P., Chiodoni, C., Portararo, P., Cappetti, B., Botti, L., Gulino, A., Isidori, A., Liso, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1098 · Cited by 35
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
